Five years after receiving just two doses of psilocybin combined with psychotherapy, an remarkable 67% of patients with clinical depression remain completely symptom-free, according to groundbreaking follow-up research from Ohio State University. The study tracked participants from a 2021 clinical trial that found psilocybin-assisted therapy effective for treating major depressive disorder, and the long-term results have exceeded researchers’ most optimistic expectations. Lead author Professor Alan Davis noted that not only did the percentage of patients in complete remission actually increase from 58% at one year to 67% at five years, but participants also showed continued improvement across anxiety, global functioning, and overall wellbeing measures.
What makes these results even more extraordinary is that patients who previously lived with debilitating depression that interfered with their capacity to engage in life now describe their condition as “more situational and manageable.” Participants consistently ranked the psilocybin therapy among the most profound and meaningful experiences of their lives, comparing it to religious conversions or the birth of children. Even when researchers assumed the worst-case scenario for participants who didn’t complete the follow-up study, the treatment still showed significant and lasting depression reduction. The study offers hope that this innovative therapy could provide durable relief for people suffering from treatment-resistant depression, with many participants reporting they gained a greater capacity for positive emotions and enthusiasm that persisted regardless of whether any depression symptoms returned.
